Document is current

Documents that mention this clinical trial

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study ^{(Post-results)}
https://doi.org/10.1136/rmdopen-2017-000607

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
https://doi.org/10.1136/rmdopen-2016-000416

SAT0192 Sarilumab suppresses thrombosis-related gene expression in circulating blood cells in mtx-ir and tnf-ir patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.5183

SAT0106 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH 1 OR >1 PRIOR TUMOR NECROSIS FACTOR INHIBITOR FAILURES
https://doi.org/10.1136/annrheumdis-2020-eular.332

FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2020-eular.1946

THU0217 Similar efficacy and safety of sarilumab 150 mg or 200 mg q2w regardless of primary (1°) or secondary (2°) failure with tnf inhibitors
https://doi.org/10.1136/annrheumdis-2018-eular.1374

FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181

THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977

FRI0240 Rheumatoid arthritis (RA) impact following treatment with sarilumab: patient reported outcomes using the raid scale from two randomized phase III trials
https://doi.org/10.1136/annrheumdis-2017-eular.3448

SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245

SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment
https://doi.org/10.1136/annrheumdis-2018-eular.3723

SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015

FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
https://doi.org/10.1136/annrheumdis-2019-eular.740

SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1373

SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275

SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
https://doi.org/10.1136/annrheumdis-2019-eular.3259

SAT0212 Sarilumab dose reduction in an open-label extension study in ra patients with inadequate response to tnf inhibitors
https://doi.org/10.1136/annrheumdis-2017-eular.5155